Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder affecting young children. The natural course of JMML is rapidly fatal with 80% of patients surviving less than three years. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment of JMML. We report a case of a 23-month-old girl who presented with an upper respiratory tract infection, fever, rash, diarrhea, hepatosplenomegaly and abdominal distention. Severe elevation of white blood cell count with monocytosis and myeloid progenitors in the peripheral blood was also detected. Bone marrow smear showed morphology suggestive of JMML, an unspecific immune phenotype and a normal karyotype. DNA analysis revealed a mutation in the ...
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disease of early childho...
advance online publication, February 25, 2014Juvenile myelomonocytic leukemia (JMML) is a fatal, mix...
mutations in PTPN11 occur in 35 % of pa-tients with de novo, nonsyndromic juvenile myelomonocytic le...
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder affecting young...
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood; it...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive hematopoietic disorder of infancy/ea...
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative neoplasm (MPN) that has a ...
2 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive hematopoietic disorder of infancy/...
Juvenile myelomonocitic leukemia (JMML) is an aggressive clonal myeloproliferative disorder (MPD) th...
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric leukemia characterized by mutations in f...
Review on juvenile myelomonocytic leukemia, with data on clinics, pathology, and involved genes
Expansion of myeloid blasts with suppression of normal hematopoiesis is a hallmark of acute myeloid ...
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disease of early childho...
advance online publication, February 25, 2014Juvenile myelomonocytic leukemia (JMML) is a fatal, mix...
mutations in PTPN11 occur in 35 % of pa-tients with de novo, nonsyndromic juvenile myelomonocytic le...
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder affecting young...
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood; it...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a rare hematopoietic malignancy, which accounts for 2 to ...
Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive hematopoietic disorder of infancy/ea...
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative neoplasm (MPN) that has a ...
2 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive hematopoietic disorder of infancy/...
Juvenile myelomonocitic leukemia (JMML) is an aggressive clonal myeloproliferative disorder (MPD) th...
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric leukemia characterized by mutations in f...
Review on juvenile myelomonocytic leukemia, with data on clinics, pathology, and involved genes
Expansion of myeloid blasts with suppression of normal hematopoiesis is a hallmark of acute myeloid ...
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disease of early childho...
advance online publication, February 25, 2014Juvenile myelomonocytic leukemia (JMML) is a fatal, mix...
mutations in PTPN11 occur in 35 % of pa-tients with de novo, nonsyndromic juvenile myelomonocytic le...